In a recent study published by Nature Communications, researchers uncovered a previously unknown method by which androgen-activated androgen receptors (ARs) increase fucosyltransferase 4 (FUT4) ...

Prostate cancer begins as an androgen-dependent tumor that undergoes clinical regression in response to pharmacological or surgical strategies that reduce testosterone concentration. Despite this ...

Clinical Implications of a Large-Scale Voluntary Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine: Preliminary Results The following represents disclosure ...

A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...

In this retrospective study, researchers sought to determine the efficacy, safety, and effectiveness of a reduced ARSI dose compared to a full dose in non-metastatic castration-resistant prostate ...

The dinuclear platinum(II) complexes inhibit prostate cancer cell growth by binding to the androgen receptor (AR) and disrupting AR-mediated gene expression. This mechanism leads to apoptosis and ...

If a prostate cancer cell were a car, the androgen receptor (AR) would be part of its ignition system, enabling cancer cells to respond to hormonal signals that drive growth. For decades, therapies ...

A meta-analysis involving 21,260 patients with advanced or metastatic prostate cancer confirms increased risks of falls and fractures with the addition of androgen receptor signaling inhibitors to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The addition of ...

“Nothing Is as Great a Learning Experience as Getting a $15,000 Bill”: A Mixed-Methods Study of Young Adult Cancer Survivors' Experience With Insurance Coverage The following represents disclosure ...